Fdabaa-24-00123, REF # FY24C1EP6, cardiovascular-kidney-metabolic (CKM) syndrome patient-reported outcome (pro) burden measure

Active Definitive Contract Awarded Last action

Contract number
75F40124C00117
Awardee
Awarding agency
Obligated
$724,461

Award facts

Contract value 100% obligated
$724,461.00 Current and potential, with all options
Completion date 74% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Cape Fear, NC 28401, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00002 · Fdabaa-24-00123, REF # FY24C1EP6, cardiovascular-kidney-metabolic (CKM) $0
Other Administrative Action P00001 $0
Original award $724,461

About this award

The Food and Drug Administration awarded a definitive contract to PPD Development LP for development of a cardiovascular-kidney-metabolic syndrome patient-reported outcome burden measure on September 11, 2024, with a ceiling value of $724,461.00 under firm fixed-price terms.

Place of performance is Cape Fear, NC. The contract has an ultimate completion date of July 15, 2027. No set-aside category was used.

Quick answers

Who was awarded contract 75F40124C00117?

75F40124C00117 was awarded to PPD Development LP by Food and Drug Administration (Department of Health and Human Services) on September 11, 2024.

How much is contract 75F40124C00117 worth?

The government has obligated $724,461 on 75F40124C00117.

Was contract 75F40124C00117 competed?

The extent of competition for 75F40124C00117 was competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award